neovascular

By Targets:	Bacterial (1) Biochemical Assay Reagents (1) CCR (2) CXCR (1) FAK (1) Integrin (4) Leukotriene Receptor (1) Liposome (4) Mitochondrial Metabolism (1) PAI-1 (1) PDGFR (1) Somatostatin Receptor (1) Src (1) SRPK (1) Tie (1) VEGFR (4)
By Research Areas:	Cancer (10) Cardiovascular Disease (10) Endocrinology (2) Infection (1) Inflammation/Immunology (4) Metabolic Disease (2) Neurological Disease (2)
Oligonucleotides:	Pegylated Lipids (3) Aptamers (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-109561

Pegaptanib sodium EYE001; NX1838	VEGFR	Metabolic Disease Inflammation/Immunology
Pegaptanib sodium is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165. Pegaptanib could be used for the study of neovascular age-related macular degeneration (AMD) .

HY-116868

Anecortave acetate Anecortave	PAI-1	Cardiovascular Disease
Anecortave acetate is a potent ocular angiostatic agent. Anecortave acetate inhibits neovascularization which is induced by many different angiogenic factors, and increases plasminogen activator inhibitor-1 (PAI-1) mRNA expression. Anecortave acetate can be used to research ocular neovascular diseases .

HY-P5840

Cyclo(RGDyC)	Biochemical Assay Reagents	Cancer
Cyclo(RGDyC) is a cyclic pentapeptide with anti-angiogenic abilities. Cyclo(RGDyC) can be combined with liposome delivery systems for research on ocular neovascular diseases and cancer .

HY-136788

ALK4290 AKST4290	CCR	Neurological Disease Inflammation/Immunology
ALK4290 (AKST4290) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a K_i of 3.2 nM for hCCR3 . ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism .

HY-120417

JP-153	Src FAK	Cardiovascular Disease
JP-153 is the Src-FAK-Paxillin signaling inhibitor. JP-153 inhibits Src-dependent phosphorylation of paxillin (Y118) and downstream activation of Akt (S473). JP-153 reduces VEGF-induced migration and proliferation in retinal endothelial cells. JP-153 can be uesd for the study of neovascular eye disease .

HY-P99905

Efdamrofusp alfa 1 Publications Verification	VEGFR	Cardiovascular Disease Neurological Disease
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .

HY-117661

SPHINX31 Maximum Cited Publications 9 Publications Verification	SRPK VEGFR	Cardiovascular Disease Cancer
SPHINX31 is a potent and selective SRPK1 inhibitor, with an IC₅₀ of 5.9 nM. SPHINX31 inhibits phosphorylation of serine/arginine-rich splicing factor 1 (SRSF1). SPHINX31 also decreases the mRNA expression of pro-angiogenic VEGF-A₁₆₅a isoform. SPHINX31 can be used to research neovascular eye disease .

HY-16467

Squalamine lactate MSI-1256F	Bacterial	Infection Cardiovascular Disease Cancer
Squalamine lactate is an aminosterol compound discovered in the tissues of the dogfish shark, with antimicrobial activity, and used for the treatment of neovascular age-related macular degeneration.

HY-P99402

Rinucumab REGN 2176	PDGFR	Metabolic Disease
Rinucumab (REGN 2176), a monoclonal antibody, is a PDGF inhibitor. Rinucumab (REGN 2176) could be used for the study of neovascular age-related macular degeneration .

HY-110161

sst2 Receptor agonist-1	Somatostatin Receptor	Cardiovascular Disease Endocrinology
sst2 Receptor agonist-1 is a potent somatostatin receptor subtype 2 (sst₂) agonist with a K_i value of 0.025 nM and a cAMP IC₅₀ value of 4.8 nM. sst2 Receptor agonist-1 can inhibit rat growth hormone (GH) secretion and ocular neovascular lesion formation. Antiangiogenic effect .

HY-136788A

ALK4290 dihydrochloride AKST4290 dihydrochloride	CCR	Inflammation/Immunology
ALK4290 dihydrochloride (AKST4290 dihydrochlorid) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a K_i of 3.2 nM for hCCR3 . ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism .

HY-119442

Quininib	Leukotriene Receptor	Cardiovascular Disease
Quininib is a cysteinyl leukotriene 1 and 2 receptor antagonist with IC₅₀s of 1.2 and 52 μM for CysLT₁R and CysLT₂R, respectively. Quininib is a potent inhibitor of developmental angiogenesis in the zebrafish eye. Quininib can be used for the research of ocular neovascular pathologies and may complement current anti-VEGF biological agents .

HY-172464

DSPE-PEG2000-cRGD	Liposome Integrin	Cancer
DSPE-PEG2000-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG2000-cRGD can be used for drug delivery .

HY-172465

DSPE-PEG5000-cRGD	Liposome Integrin	Cancer
DSPE-PEG5000-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG5000-cRGD can be used for drug delivery .

HY-172464A

DSPE-PEG3400-cRGD	Liposome Integrin	Cancer
DSPE-PEG3400-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG3400-cRGD can be used for drug delivery .

HY-172463

DSPE-PEG1000-cRGD	Liposome Integrin	Cancer
DSPE-PEG1000-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG1000-cRGD can be used for drug delivery .

HY-P99546

Trebananib 2xCon4C; AMG 386	Tie	Cardiovascular Disease Cancer
Trebananib (2xCon4C; AMG 386) is an Fc fusion peptibody that prevents Tie2 receptor activation through binding of both angiopoietin 1 (Ang1) and Ang2. Trebananib has anti-angiogenesis activity .

HY-162904

BPU17	Mitochondrial Metabolism	Cardiovascular Disease
BPU17 binds to PHB1 and causes mild defects in mitochondrial function by defects in the PHB1-PHB2 interaction. This impairment inhibits the SRF/CArG-box-dependent transcription, resulting in the suppression of epithelial-mesenchymal transition (EMT) of retinal pigment epithelial cells (RPEs). BPU17 exhibits antifibrotic activity in vivo. BPU17 is promising for research of anti-neovascular age-related macular degeneration (nAMD) agent .

HY-19867A

Burixafor hydrobromide 2 Publications Verification TG-0054 hydrobromide	CXCR VEGFR	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Burixafor (TG-0054) hydrobromide is a selective, orally active CXCR4 antagonist that effectively blocks the interaction between CXCR4 and its ligand, stromal cell-derived factor SDF-1. Burixafor hydrobromide interferes with the SDF-1/CXCR4 signaling pathway, prompting the release of bone marrow stem cells into the peripheral circulation, exerting immunomodulatory and anti-inflammatory activities. Burixafor hydrobromide can be used in the study of cancer, Intraocular neovascular diseases (such as choroidal neovascularization), myocardial infarction and other diseases, with the potential to mobilize stem cells, improve cardiac function and reduce inflammatory responses .

Cat. No.	Product Name	Type

HY-172464

DSPE-PEG2000-cRGD	Drug Delivery
DSPE-PEG2000-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG2000-cRGD can be used for drug delivery .

HY-172465

DSPE-PEG5000-cRGD	Drug Delivery
DSPE-PEG5000-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG5000-cRGD can be used for drug delivery .

HY-172464A

DSPE-PEG3400-cRGD	Drug Delivery
DSPE-PEG3400-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG3400-cRGD can be used for drug delivery .

HY-172463

DSPE-PEG1000-cRGD	Drug Delivery
DSPE-PEG1000-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG1000-cRGD can be used for drug delivery .

Cat. No.	Product Name	Target	Research Area

HY-P5840

Cyclo(RGDyC)	Biochemical Assay Reagents	Cancer
Cyclo(RGDyC) is a cyclic pentapeptide with anti-angiogenic abilities. Cyclo(RGDyC) can be combined with liposome delivery systems for research on ocular neovascular diseases and cancer .

HY-P5840A

Cyclo(RGDyC) TFA	Peptides	Cancer
Cyclo(RGDyC) TFA is a cyclic pentapeptide with anti-angiogenic abilities. Cyclo(RGDyC) TFA can be combined with liposome delivery systems for research on ocular neovascular diseases and cancer .

Cat. No.	Product Name	Target	Research Area

HY-P99905

Efdamrofusp alfa 1 Publications Verification	VEGFR	Cardiovascular Disease Neurological Disease
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .

HY-P99402

Rinucumab REGN 2176	PDGFR	Metabolic Disease
Rinucumab (REGN 2176), a monoclonal antibody, is a PDGF inhibitor. Rinucumab (REGN 2176) could be used for the study of neovascular age-related macular degeneration .

HY-P99546

Trebananib 2xCon4C; AMG 386	Tie	Cardiovascular Disease Cancer
Trebananib (2xCon4C; AMG 386) is an Fc fusion peptibody that prevents Tie2 receptor activation through binding of both angiopoietin 1 (Ang1) and Ang2. Trebananib has anti-angiogenesis activity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-16467

Squalamine lactate MSI-1256F	Infection Cardiovascular Disease Triterpenes Structural Classification Animals Classification of Application Fields Terpenoids Marine natural products Other marine organisms Disease Research Fields	Bacterial
Squalamine lactate is an aminosterol compound discovered in the tissues of the dogfish shark, with antimicrobial activity, and used for the treatment of neovascular age-related macular degeneration.

Cat. No.	Product Name		Classification

HY-109561

Pegaptanib sodium EYE001; NX1838		Aptamers
Pegaptanib sodium is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165. Pegaptanib could be used for the study of neovascular age-related macular degeneration (AMD) .

HY-172464

DSPE-PEG2000-cRGD		Pegylated Lipids
DSPE-PEG2000-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG2000-cRGD can be used for drug delivery .

HY-172465

DSPE-PEG5000-cRGD		Pegylated Lipids
DSPE-PEG5000-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG5000-cRGD can be used for drug delivery .

HY-172463

DSPE-PEG1000-cRGD		Pegylated Lipids
DSPE-PEG1000-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG1000-cRGD can be used for drug delivery .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Oligonucleotides

neovascular

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Oligonucleotides

Natural
Products